Our findings suggest that MBP may play an important role in the pathogenesis of MSA and highlight the potential of targeting remyelination pathways, particularly MBP regulation, as a novel therapeutic approach to modifying disease progression. The gene discussed is MBP; the disease is multiple system atrophy.